Structure Therapeutics Statistics
 Total Valuation
 GPCR has a market cap or net worth of $1.90 billion. The enterprise value is $1.13 billion.
 Important Dates
 The next estimated earnings date is Thursday, November 13, 2025, after market close.
 | Earnings Date | Nov 13, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
 GPCR has 57.60 million shares outstanding. The number of shares has increased by 27.00% in one year.
 | Current Share Class | n/a | 
| Shares Outstanding | 57.60M | 
| Shares Change (YoY) | +27.00% | 
| Shares Change (QoQ) | +0.35% | 
| Owned by Insiders (%) | 5.84% | 
| Owned by Institutions (%) | 86.64% | 
| Float | 44.53M | 
Valuation Ratios
  | PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | n/a | 
| Forward PS | n/a | 
| PB Ratio | 2.40 | 
| P/TBV Ratio | 2.47 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
 Financial Ratio HistoryEnterprise Valuation
  | EV / Earnings | n/a | 
| EV / Sales | n/a | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | n/a | 
Financial Position
 The company has a current ratio of 20.48, with a Debt / Equity ratio of 0.01.
 | Current Ratio | 20.48 | 
| Quick Ratio | 20.15 | 
| Debt / Equity | 0.01 | 
| Debt / EBITDA | n/a | 
| Debt / FCF | n/a | 
| Interest Coverage | n/a | 
Financial Efficiency
 Return on equity (ROE) is -21.14% and return on invested capital (ROIC) is -16.10%.
 | Return on Equity (ROE) | -21.14% | 
| Return on Assets (ROA) | -15.57% | 
| Return on Invested Capital (ROIC) | -16.10% | 
| Return on Capital Employed (ROCE) | -28.26% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | -$1.10M | 
| Employee Count | 163 | 
| Asset Turnover | n/a | 
| Inventory Turnover | n/a | 
Taxes
 In the past 12 months, GPCR has paid $465,000 in taxes.
 | Income Tax | 465,000 | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
 The stock price has decreased by -13.05% in the last 52 weeks. The beta is -1.76, so GPCR's price volatility has been lower than the market average.
 | Beta (5Y) | -1.76 | 
| 52-Week Price Change | -13.05% | 
| 50-Day Moving Average | 24.92 | 
| 200-Day Moving Average | 22.62 | 
| Relative Strength Index (RSI) | 73.51 | 
| Average Volume (20 Days) | 866,055 | 
Short Selling Information
  | Short Interest | 4.85M | 
| Short Previous Month | 6.37M | 
| Short % of Shares Out | 8.42% | 
| Short % of Float | 10.89% | 
| Short Ratio (days to cover) | 4.49 | 
Income Statement
  | Revenue | n/a | 
| Gross Profit | n/a | 
| Operating Income | -219.66M | 
| Pretax Income | -178.49M | 
| Net Income | -178.95M | 
| EBITDA | -218.55M | 
| EBIT | -219.66M | 
| Earnings Per Share (EPS) | -$3.12 | 
 Full Income StatementBalance Sheet
 The company has $786.50 million in cash and $7.68 million in debt, giving a net cash position of $778.82 million or $13.52 per share.
 | Cash & Cash Equivalents | 786.50M | 
| Total Debt | 7.68M | 
| Net Cash | 778.82M | 
| Net Cash Per Share | $13.52 | 
| Equity (Book Value) | 772.08M | 
| Book Value Per Share | 13.41 | 
| Working Capital | 760.27M | 
 Full Balance SheetCash Flow
 In the last 12 months, operating cash flow was -$162.95 million and capital expenditures -$1.25 million, giving a free cash flow of -$164.20 million.
 | Operating Cash Flow | -162.95M | 
| Capital Expenditures | -1.25M | 
| Free Cash Flow | -164.20M | 
| FCF Per Share | -$2.85 | 
 Full Cash Flow StatementMargins
  | Gross Margin | n/a | 
| Operating Margin | n/a | 
| Pretax Margin | n/a | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
 GPCR does not appear to pay any dividends at this time.
 | Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -27.00% | 
| Shareholder Yield | -27.00% | 
| Earnings Yield | -9.39% | 
| FCF Yield | -8.61% | 
 Analyst Forecast
 The average price target for GPCR is $69.57, which is 110.82% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target | $69.57 | 
| Price Target Difference | 110.82% | 
| Analyst Consensus | Strong Buy | 
| Analyst Count | 8 | 
| Revenue Growth Forecast (5Y) | n/a | 
| EPS Growth Forecast (5Y) | -24.27% | 
 Stock ForecastsFair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
 This stock does not have any record of stock splits.
 | Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
  | Altman Z-Score | n/a | 
| Piotroski F-Score | 1 |